Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782s

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 3, 2013, Pages 514-527

  Lavreysen, Hilde ^a   Langlois, Xavier ^a   Ahnaou, Abdel ^a   Drinkenburg, Wilhelmus ^a   Te Riele, Paula ^a   Biesmans, Ilse ^a   Van Der Linden, Ilse ^a   Peeters, Luc ^a   Megens, Anton ^a   Wintmolders, Cindy ^a   Cid, Jose Maria ^a   Trabanco, Andrés A ^a   Andrés, Jose Ignacio ^a   Dautzenberg, Frank M ^a   Lütjens, Robert ^b   Macdonald, Gregor ^a   Atack, John R ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Addex Therapeutics SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 CYANO 1 CYCLOPROPYLMETHYL 4 (4 PHENYL PIPERIDIN 1 YL)PYRIDINE 2(1H) ONE; BRAIN RECEPTOR; JNJ 40068782; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; TRITIUM; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG PENETRATION; DRUG STRUCTURE; FEMALE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REM SLEEP; SINGLE DRUG DOSE; SLEEP WAKING CYCLE;

AMINO ACIDS; ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; BRAIN CHEMISTRY; CALCIUM; CELL MEMBRANE; CEREBRAL CORTEX; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOPROPANES; EXCITATORY AMINO ACID AGENTS; EXCITATORY AMINO ACID AGONISTS; GLYCINE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; ISOTOPE LABELING; LIGANDS; MALE; MICE; MOTOR ACTIVITY; PIPERIDINES; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SLEEP; TRITIUM; XANTHENES;

EID: 84882429621     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.204990     Document Type: Article

References (55)

1. Ahnaou A, Dautzenberg FM, Geys H, Imogai H, Gibelin A, Moechars D, Steckler T, and Drinkenburg WH (2009) Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol 603:62-72.
2. Al-Shamma HA, Anderson C, Chuang E, Luthringer R, Grottick AJ, Hauser E, Morgan M, Shanahan W, Teegarden BR, and Thomsen WJ, et al. (2010) Nelotanserin, a novel selecti ve human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther 332:281-290.
3. Auerbach BD, Osterweil EK, and Bear MF (2011) Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480:63-68.
4. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
5. Cid-Nunez JM, Trabanco-Suarez AA, Macdonald GJ, Duvey GAJ (2008), inventors; Janssen Pharmaceutica NV, Belgium and Addex Pharma S.A., assignees. Preparation of 3-cyano-4-(4-tetrahydropyran-phenyl)pyridin-2-one derivatives as positive mGluR2 receptor modulators. WO 2008107481 A1. 2008 Sept 12.
6. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
7. Conn PJ, Lindsley CW, and Jones CK (2008) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30:25-31.
8. Cosford ND, Roppe J, Tehrani L, Schweiger EJ, Seiders TJ, Chaudary A, Rao S, and Varney MA (2003) [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 13:351-354.
9. Dash MB, Douglas CL, Vyazovskiy VV, Cirelli C, and Tononi G (2009) Long-term homeostasis of extracellular glutamate in the rat cerebral cortex across sleep and waking states. J Neurosci 29:620-629.
10. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, and Tollefson GD (2008) Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33:1603-1610.
11. Feinberg I, Campbell IG, Schoepp DD, and Anderson K (2002) The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat. Pharmacol Biochem Behav 73:467-474.
12. Fell MJ, McKinzie DL, Monn JA, and Svensson KA (2012) Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 62:1473-1483.
13. Fell MJ, Svensson KA, Johnson BG, and Schoepp DD (2008) Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4- amino-2- sulfonylbicyclo[3.1.0]hexane-4,6-d icarboxylic acid (LY404039). J Pharmacol Exp Ther 326:209-217.
14. Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, Rorick-Kehn L, Overshiner CD, Rasmussen K, and Chaney SF, et al. (2011) N-(4-((2- (trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl) -1-methyl-1Himidazole- 4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling s uggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther 336:165-177.
15. Galici R, Echemendia NG, Rodriguez AL, and Conn PJ (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315:1181-1187.
16. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, and Conn PJ (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318:173-185.
17. Gasparini F, Andres H, Flor PJ, Heinrich M, Inderbitzin W, Lingenhöhl K, Müller H, Munk VC, Omilusik K, and Stierlin C, et al. (2002) [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett 12:407-409.
18. Grillon C, Cordova J, Levine LR, and Morgan CA, 3rd (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fearpotentiated startle paradigm in humans. Psychopharmacology (Berl) 168: 446-454.
19. Gu G, Lorrain DS, Wei H, Cole RL, Zhang X, Daggett LP, Schaffhauser HJ, Bristow LJ, and Lechner SM (2008) Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition. Brain Res 1197:47-62.
20. Happe HK, Bylund DB, and Murrin LC (2001) Agonist-stimulated [35S]GTPgammaS autoradiography: optimization for high sensitivity. Eur J Pharmacol 422:1-13.
21. Helton DR, Tizzano JP, Monn JA, Schoepp DD, and Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284: 651-660.
22. Hill DR, Campbell NJ, Shaw TM, and Woodruff GN (1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci 7:2967-2976.
23. Hlavackova V, Goudet C, Kniazeff J, Zikova A, Maurel D, Vol C, Trojanova J, Prézeau L, Pin J-P, and Blahos J (2005) Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J 24:499-509.
24. Imogai HJ, Cid-Nunez JM, Andres-Gil JI, Trabanco-Suarez AA, Oyarzabal Santamarina J, Dautzenberg FM, Macdonald GJ, Pullan SE, Lutjens RJ, Duvey GAJ, Nhem V, Finn TP, and Melikyan G (2008), inventors; Janssen Pharmaceutica N.V., Belgium and Addex Pharmaceuticals S.A., assignees. 1,4-Disubstituted 3-cyanopyridone derivatives and their use as positive allosteric modulators of mGlu2- receptors and their preparation. WO 2007104783 A2.
25. Johnson MP, Baez M, Jagdmann GE, Jr, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, and Schoepp DD (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N- (4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3- ylmethylamine. J Med Chem 46:3189-3192.
26. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP,and Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 179: 271-283.
27. Kew JN and Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179:4-29.
28. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, and Jarkova N; HBBI Study Group (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate i n patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31:349-355.
29. Kniazeff J, Bessis A-S, Maurel D, Ansanay H, Prézeau L, and Pin J-P (2004) Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat Struct Mol Biol 11:706-713.
30. Langmead CJ (2012) Ligand properties and behaviours in an allosteric age. Trends Pharmacol Sci 33:621-622.
31. Lavreysen H and Dautzenberg FM (2008) Therapeutic potential of group III metabotropic glutamate receptors. Curr Med Chem 15:671-684.
32. Lavreysen H, Janssen C, Bischoff F, Langlois X, Leysen JE, and Lesage AS (2003) [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol 63:1082-1093.
33. Linden AM, Shannon H, Baez M, Yu JL, Koester A, and Schoepp DD (2005) Anxiolytic-like activity of the mGlu2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out m ice. Psychopharmacology (Berl) 179:284-291.
34. Lopez-Rodriguez F, Medina-Ceja L, Wilson CL, Jhung D, and Morales-Villagran A (2007) Changes in extracellular glutamate levels in rat orbitofrontal cortex during sleep and wakefulness. Arch Med Res 38:52-55.
35. Mezler M, Geneste H, Gault L, and Marek GJ (2010) LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs 11:833-845.
36. Michelson D, Levine LR, Dellva MA, Mesters P, Schoepp DD, Dunayevich E, and Tollefson GD (2005) Clinical studies with mGlu2/3 receptor agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Neuropharmacology 49 (Suppl 1):257.
37. Niswender CM and Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50:295-322.
38. Ohishi H, Neki A, and Mizuno N (1998) Distribution of a metabotropic glutamate recepto r, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody. Neurosci Res 30:65-82.
39. Ohishi H, Shigemoto R, Nakanishi S, and Mizuno N (1993) Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 53:1009-1018.
40. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, and Morozova MA, et al. (2007) Activation of mGlu2/ 3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13:1102-1107.
41. Pinkerton AB, Cube RV, Hutchinson JH, James JK, Gardner MF, Rowe BA, Schaffhauser H, Rodriguez DE, Campbell UC, and Daggett LP, et al. (2005) Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorg Med Chem Lett 15:1565-1571.
42. Richards G, Messer J, Malherbe P, Pink R, Brockhaus M, Stadler H, Wichmann J, Schaffhauser H, and Mutel V (2005) Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPgammas binding. J Comp Neurol 487:15-27.
43. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, and McKinzie DL, et al. (2007) In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 193:121-136.
44. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, and Vernier JM, et al. (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64:798-810.
45. Schoepp DD, Wright RA, Levine LR, Gaydos B, and Potter WZ (2003) LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6: 189-197.
46. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, and Schreiber R (2003) Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257 -277.
47. Spooren WP, Gasparini F, van der Putten H, Koller M, Nakanishi S, and Kuhn R (2000) Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol 397:R1-R2.
48. Steckler T, Lavreysen H, Oliveira AM, Aerts N, Van Craenendonck H, Prickaerts J, Megens A, and Lesage AS (2005) Effects of mGlu1 receptor blockade on anxietyrelated behaviour in the rat lick suppression test. Psychopharmacology (Berl) 179: 198-206.
49. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, and Sc hoepp DD (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131-144.
50. Tatarczynska E, Kodzinska A, Kroczka B, Chojnacka-Wójcik E, and Pilc A (2001) The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology (Berl) 158:94-99.
51. Tizzano JP, Griffey KI, and Schoepp DD (2002) The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 73:367-374.
52. Varney MA and Gereau RW, 4th (2002) Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr Drug Targets CNS Neurol Disord 1:283-296.
53. Witkin JM, Marek GJ, Johnson BG, and Schoepp DD (2007) Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 6: 87-100.
54. Woolley ML, Pemberton DJ, Bate S, Corti C, and Jones DNC (2008) The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 196:431-440.
55. Wright RA, Johnson BG, Zhang C, Salhoff C, Kingston AE, Calligaro DO, Monn JA, Schoepp DD, and Marek GJ (2013) CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [3H]LY459477 autoradiography. Neuropharmacology 66:89-98.